Journal of Antimicrobial Chemotherapy (1999) 44, 819-822
© 1999 The British Society for Antimicrobial Chemotherapy
Brief report |
Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria
Department of Antimicrobial Chemotherapy, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, UK
Tentative MIC and zone diameter breakpoints were determined for moxifloxacin using
BSAC criteria. An MIC breakpoint of 
1 mg/L, denoting sensitivity, is suggested for
Enterobacteriaceae, staphylococci, haemophili, moraxellae, pneumococci and enterococci. For
pseudomonads high and low breakpoints of 4 mg/L and 1 mg/L are suggested to allow for an
intermediate category of sensitivity. A 1 µg moxifloxacin disc content is suggested for
testing all of the organisms previously mentioned, except pseudomonads, for which a 5 µg
disc is needed to discriminate between the intermediate and sensitive populations. Corresponding
zone diameter breakpoints for a 1 µg disc are 
20 mm for Enterobacteriaceae and
staphylococci, 18 mm for the respiratory pathogens (Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis) and 15 mm for enterococci. For
Pseudomonas aeruginosa with a 5 µg disc, three bands are suggested for
interpretation, that of 25 mm (sensitive), 18-24 mm (intermediate) and 17 mm
(resistant).
* Corresponding author. Tel: +44-121-554-3801; Fax: +44-121-551-7763.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Andrews, J. P. Ashby, G. Jevons, and R. Wise Determination of in vitro susceptibility to ABT-492 by BSAC standardized methodology J. Antimicrob. Chemother., September 1, 2003; 52(3): 526 - 527. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Rautelin, A. Vierikko, M.-L. Hanninen, and M. Vaara Antimicrobial Susceptibilities of Campylobacter Strains Isolated from Finnish Subjects Infected Domestically or from Those Infected Abroad Antimicrob. Agents Chemother., January 1, 2003; 47(1): 102 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. MacKenzie, K. E. Milne, and I. M. Gould Calculation of composite recovery time: a new pharmacodynamic parameter J. Antimicrob. Chemother., August 1, 2002; 50(2): 281 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-T. Wang, L. C. McDonald, S.-C. Chang, and M. Ho Community-Acquired Acinetobacter baumannii Bacteremia in Adult Patients in Taiwan J. Clin. Microbiol., April 1, 2002; 40(4): 1526 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Andrews and R. Wise In vitro susceptibility testing of BMS-284756 by the BSAC standardized disc testing method J. Antimicrob. Chemother., August 1, 2001; 48(2): 322 - 324. [Full Text] [PDF]
|
|
|
|
|
|
P. L. Ho, W. C. Yam, T. L. Que, D. N. C. Tsang, W. H. Seto, T. K. Ng, and W. S. Ng Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones J. Antimicrob. Chemother., May 1, 2001; 47(5): 655 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, M. Warner, R. C. George, and D. M. Livermore Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales J. Antimicrob. Chemother., April 1, 2001; 47(4): 411 - 415. [Abstract] [Full Text] [PDF]
|
|